dc.creator | Versiani, M. | |
dc.creator | Amrein, R. | |
dc.creator | Stabl, M. | |
dc.creator | Magistris, | |
dc.creator | Udabe, R. Ucha | |
dc.creator | Da Costa, Delcir A. | |
dc.creator | Nardi, A. E. | |
dc.creator | Versiani, M. | |
dc.creator | Capponi, R. | |
dc.date.accessioned | 2019-01-29T15:54:59Z | |
dc.date.available | 2019-01-29T15:54:59Z | |
dc.date.created | 2019-01-29T15:54:59Z | |
dc.date.issued | 1997 | |
dc.identifier | International Clinical Psychopharmacology, Volumen 12, Issue 4, 2018, Pages 183-193 | |
dc.identifier | 02681315 | |
dc.identifier | https://repositorio.uchile.cl/handle/2250/162750 | |
dc.description.abstract | An international, multicenter, placebo-controlled study was undertaken to determine the safety and antidepressant efficacy of moclobemide, a new reversible inhibitor of monoamine oxidase A, and imipramine in the treatment of dysthymia (DSM-III-R). A total of 315 patients were enrolled and randomly assigned to an 8-week treatment in one of three groups (moclobemide, imipramine and placebo). Patients were male or female outpatients aged between 18 and 65 years meeting DSM III-R criteria for dysthymia, primary type, with late or early onset. Of the patients in each group 85% completed the 8-week treatment period. The percentage of patients who no longer fulfilled DSM-III-R symptom criteria at treatment end-point was significantly higher in the moclobemide (60%) and imipramine (49%) treatment groups than in the placebo group (22%). Differences to placebo were also statistically significant both for moclobemide and for imipramine on the other efficacy variables (i.e. Hamilton Rating Scale f | |
dc.language | en | |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ | |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Chile | |
dc.source | International Clinical Psychopharmacology | |
dc.subject | Antidepressant | |
dc.subject | Chronic disease | |
dc.subject | Chronic minor depression | |
dc.subject | Depressive disorder | |
dc.subject | Double-blind Double depression | |
dc.subject | Drug treatment | |
dc.subject | Dysthymia | |
dc.subject | Dysthymic disorder | |
dc.subject | Imipramine | |
dc.subject | Moclobemide | |
dc.subject | Monoamine oxidase inhibitor | |
dc.subject | Placebo | |
dc.subject | RIMA | |
dc.subject | TCA | |
dc.title | Moclobemide and imipramine in chronic depression (dysthymia): An international double-blind, placebo-controlled trial | |
dc.type | Artículo de revista | |